Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis

The efficacy of tyrosine kinase inhibitor (TKI)-based therapy after previous immuno-oncology therapy (IO) failure has been addressed before. However, summary efficacy estimates have never been generated in these reports. We addressed this void. We systematically examined TKI efficacy after IO-failur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2021-09, Vol.155, p.245-255
Hauptverfasser:	Wenzel, Mike, Deuker, Marina, Nocera, Luigi, Collà Ruvolo, Claudia, Würnschimmel, Christoph, Tian, Zhe, Shariat, Shahrokh F., Saad, Fred, Briganti, Alberto, Tilki, Derya, Graefen, Markus, Kluth, Luis A., Becker, Andreas, Roos, Frederik C., Chun, Felix K.H., Karakiewicz, Pierre I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer immunotherapy Checkpoint inhibitor Enzyme inhibitors Estimates Failure Female Humans Kidney cancer Kidney Neoplasms - drug therapy Kinases Male Meta-analysis Metastases Neoplasm Metastasis Oncology Progression-free survival Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Renal cell carcinoma Subsequent therapy Systematic review Therapy Time Factors TKI Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!